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Alzheimer’s disease (AD) is a progressive, neurodegenerative disease that creates
complex challenges and a significant burden for patients and caregivers. Although
underlying pathological changes due to AD may be detected in research studies decades
prior to symptom onset, many patients in the early stages of AD remain undiagnosed in
clinical practice. Increasing evidence points to the importance of an early and accurate
AD diagnosis to optimize outcomes for patients and their families, yet many barriers
remain along the diagnostic journey. Through a series of international working group
meetings, a diverse group of experts contributed their perspectives to create a blueprint
for a patient-centered diagnostic journey for individuals in the early stages of AD and
an evolving, transdisciplinary care team. Here, we discuss key learnings, implications,
and recommendations.
Keywords: Alzheimer’s disease, dementia, early detection, diagnosis, mild cognitive impairment

INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disease associated with high monetary
costs and burden of care (1). The presentation of AD encompasses a continuum that extends
from asymptomatic individuals with pathological evidence of AD (i.e., preclinical AD) (2) to
patients with mild cognitive impairment (MCI) due to AD (the first clinically detectable stage of
disease) and finally to patients with AD dementia (3). Pathological hallmarks of AD, β-amyloid
plaques and neurofibrillary tangles, may be detectable in the brain decades before clinical symptoms
appear (3). Many individuals with early-stage AD remain undiagnosed, as subtle cognitive deficits
may not overtly impair activities of daily living. Subtle changes may be interpreted as normal
aging by patients, family, and healthcare providers (HCPs) (4). As the disease progresses into AD
dementia, symptoms of cognitive decline become more obvious, disrupt activities of daily living
more frequently, and may prompt patients to seek medical attention (5).
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An accurate diagnosis in the early stages of disease is critical
for prognosis and advanced-care planning (1). Although an
approved treatment for the early stages of AD that might delay
disease progression is not yet available, a delayed AD diagnosis
postpones the initiation of advanced-care planning and nonpharmacological interventions, such as cognitive stimulation,
psychological treatment, and lifestyle changes that may preserve
cognitive function or improve quality of life (6–9). Lifestyle
modifications and enhanced social support may lessen caregiver
burden, delay institutionalization, and reduce healthcare costs
(10). Overall, a timely and accurate diagnosis is key to developing
an effective care plan, which requires coordination between the
patient, caregivers, family members, HCPs, specialists, social
services, and payers (5).
The early and accurate diagnosis of AD for people in the
United States born in and prior to 2018 could result in a
cumulative savings of approximately $7 trillion in medical
and care costs (1). Despite mounting evidence supporting
the benefits of early detection (10–12) and studies indicating
that most patients and caregivers would prefer disclosure of
an AD diagnosis (13), the current process for diagnosis in
the early stages of AD needs improvement (14). Although
the recently published US Preventive Services Task Force
Recommendation Statement concluded there is insufficient
evidence to properly weigh the benefits and risks of screening
for cognitive impairment in older adults (15), experts have been
quick to contextualize these results, emphasizing the current
benefits of screening for MCI and noting that approval of
therapies targeting the underlying pathophysiology of AD would
add further value to early screening (16).
Globally, approximately 82 million people will have dementia
by 2030 at a cost of $2 trillion per year (17); 60 to 80% of
these cases are likely to be caused by AD (1). To properly
screen and manage the growing population of potential patients,
increased resources are needed. In the current system, individuals
suspected of having AD may become entangled in a cycle of
continuous referrals, waiting years for a diagnosis or treatment
(4). Without an early-detection paradigm in place, the alreadylimited infrastructure will be further strained by an influx
of patients seeking treatment once a therapy targeting the
underlying pathophysiology of AD is approved (14).
Interventions that target AD pathophysiology are
hypothesized to be more successful when applied earlier in
the course of AD, before significant neurodegeneration occurs
(2, 18, 19). If such a therapy becomes available, one of the
largest constraints to its use is projected to be the limited
availability of specialists to evaluate and diagnose patients (14).
Although the shortage of trained specialists cannot be quickly
remedied, developing and implementing strategies to improve
the current infrastructure and focus on patient-centric care
is feasible.
To better understand how to improve the diagnostic
journey of patients in the early stages of AD, a series of three
international working group meetings was convened between
April 2016 and May 2017. Contributors represented diverse
specialties, including geriatrics, internal medicine, neurology,
neuropsychology, nursing, pharmacology, and psychiatry.
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One-on-one interviews with contributors were conducted to
gather insights from personal practice experience to identify
similarities and differences in care models. These meetings were
organized and held with the unrestricted support of Biogen,
with an emphasis on currently available interventions and
agnostic to any investigational therapy in clinical development.
Here, we present the perspectives and recommendations of
this group.

PROPOSED BLUEPRINT FOR AD
DIAGNOSIS AND CARE IN THE EARLY
STAGES OF AD
Through an iterative meeting process, the working group came
to the consensus recommendation to establish a patient-centered
diagnosis journey for individuals with early-stage AD (Figure 1).
This journey is comprised of the following five stages: detect,
assess, differentiate, diagnose, and treat and monitor. The diverse
HCP working group applied key learnings and implications
from its collective insights to create a blueprint for an evolving,
transdisciplinary care team to support this diagnosis journey
(Figure 1).
In clinical practice, the term “screening” is used by patients
and other HCPs to broadly refer to many types of tools and
practices that aid in making a diagnosis at an early disease
stage. The working group realized that screening needed to be
subdivided based on which HCPs and tools were likely to be
involved. The initial detection stage may occur in a variety of
scenarios where HCPs are made aware of cognitive concerns
or first signs of cognitive impairment. The subsequent stages,
assessing individuals for cognitive impairment and/or a high
likelihood of AD pathology and differentiating AD from other
causes of cognitive impairment, will require more specialized
training. To fulfill this need, the working group recommends
the introduction of an AD-specialist role across a variety of
disciplines to diagnose early-stage AD. Following diagnosis of AD
via biomarker testing and determination of treatment options by
a dementia specialist, treatment and monitoring of patients may
be entrusted to a patient-centered, transdisciplinary team with
a variety of expertise and skills to meet the needs of the patient
and caregiver.
This manuscript provides a working template for how a
clinical team may operate at each step of diagnosis with active
suggestions to implement training and build a collaborative
team infrastructure. We identified three important focus areas
(Table 1) central to achieving this, including: (a) increasing
awareness of the benefits of diagnosis in the early stages of
AD; (b) developing patient-centered support via the integrated
AD care team blueprint; and (c) strengthening infrastructure
to create the processes and capacity required to create these
care teams. The implementation of this paradigm may not
only improve current patient care, but also prepare our
healthcare system for the anticipated increasing number of
patients with AD who seek care following the approval of
one or more investigational therapies targeting the underlying
pathophysiology of AD (20, 21).
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FIGURE 1 | Proposed blueprint for pathways of entry into an integrated AD care team and potential roles of HCPs within the AD care team. AD, Alzheimer’s disease;
cog, cognitive; HCP, healthcare professional; MRI, magnetic resonance imaging; NP, nurse practitioner; PCP, primary care physician.

Detect

reimbursement of cognitive screening exist (e.g., the Medicare
Annual Wellness Visit), the prevailing pattern suggests that few
HCPs take advantage of these options (5). Patients with AD are
highly diverse, and the nuanced symptoms of the disease, paired
with diverse family histories, comorbidities, cultural beliefs, and
socioeconomic backgrounds, lead to variable entry points into
the AD care system. To facilitate points of entry into early-stage
AD care, the working group agreed that increasing awareness
and identification of early-stage AD is imperative and composes
Focus Area 1 (Table 1A).
In the general population, understanding that management
options currently exist for AD may motivate more patients to
discuss cognitive complaints with their HCPs or families to
encourage their loved ones to discuss these problems with their

Detecting early stages of AD (e.g., MCI due to AD and mild
AD dementia) in the clinic may occur in a variety of scenarios
(Figure 1A). Some proactive patients with a family history of
dementia but no evidence of symptoms or those with subjective
cognitive impairment may seek a dementia specialist on their
own. However, cognitive symptoms are often detected in other
scenarios: in patients’ discussions about memory with an HCP
at annual wellness visits or with non-AD specialists treating
other comorbidities. These discussions may be limited due to
a patient’s reticence to discuss minor cognitive complaints, the
common belief that cognitive decline is a normal part of aging,
and/or an HCP’s limited time, training, or resources to routinely
screen for cognitive impairment. Although mechanisms for

Frontiers in Neurology | www.frontiersin.org
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TABLE 1 | Focus areas to improve AD care.
A. Focus area 1: establish awareness
Raise awareness of
clinical value for early
detection

Educate about what to look
for during early detection

Train nondementia-focused
HCPs to act for their patients
with early-stage AD

Design an ideal process to
detect patients with
early-stage AD

Tactics

• Build awareness in the
general population,
including with patients
and care partners
• Educate
non-dementia-trained
HCPs about the clinical
value of early detection

• Collect data from population
databases and registries to
identify risk factors and detect
early-stage AD
• Collect individual
longitudinal data

• Train HCPs to proactively
detect and support the patient
• Train HCPs to refer the patient
to a dementia care team

• Follow an accessible, stepby-step process, designed to
stratify patient risk and help
HCPs determine if a patient
continues to assessment
• Patient questionnaire: Assess
for risk of cognitive impairment
• Risk stratification: Build risk
profile for cognitive impairment
• Care team refer: Referrals per
cognitive impairment profile

Guidance and
examples

• AD experts to promote
broad communication
and disseminate available
materials
• Partner with large
specialty centers and
geriatric groups
• Targeted information for
specific subpopulations
• Leverage web-based,
nontraditional, and
established channels

• Include information such as
age, sex, race, education, and
norms for each patient in
databases for context
• Must caution that outcomes
can vary
• Could support future
mobile monitoring

• Train HCPs in diagnosis
(including cognitive tests and
available biomarkers)
• Provide clear guidance for
HCPs regarding current
reimbursement codes
• Characterize the HCP as a
sentinel to refer patients to
specialists
• Provide referral analysis and
support
• Be available for outreach,
tools, and
communication support

• Appeal to policy makers to
design new reimbursement
codes focused on early
detection of disease with
feasible requirements for
primary care providers

B. Focus area 2: develop patient-centered support
Create a care coordination team to help patients navigate
their journey

Increase access to services and information to increase
patient engagement

Resources required

• Training programs or certifications within clinic or larger
healthcare system, such as a specialized program for interested
nurses
• Initiatives to impact policy around paying for these changes; can
use grants for some clinics
• Large group of volunteers, either intrinsically motivated or
leveraging those already in settings like nursing homes, to
disseminate nonexpert info
• A patient resource toolbox
• A clear economic case for additional resources

• Existing or new web platform
• Designated individuals to respond to questions and proactively
contact concerned patients and care partners (care coordinator;
see previous recommendation)

Potential impact

• Eases patient and care partner stress associated with the
diagnostic process (leading up to and after diagnosis)
• Helps destigmatize AD
• Empowers patients to seek clinics and care
• Increases the quality of patient-to–healthcare system
conversations, ensuring that the right information gets to
patients when they need it
• Increases capacity of HCPs
• Improves patient adherence to recommendations

• Eases patient and care partner stress associated with the
diagnostic process (leading up to and after diagnosis)
• Helps destigmatize AD
• Empowers patients to seek clinics and care; positions patients
to be their own advocates
• Increases the quality of patient-to–healthcare system
conversations, ensuring that the right information gets to the
right patient at the right time
• Protects patients from misinformation/predators by giving them
increased access to quality information
• Increases number of potential patients with AD in the system
receiving optimal care
• Increases detection of early-stage AD
• Increases capacity of HCPs
• Decreases patient dropout rates and improves adherence
and persistence
(Continued)
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TABLE 1 | Continued
Guidance and
examples

In a comprehensive clinic:
• Designated person within clinic to help patients navigate journey
• Care coordination team may be a certified volunteer group
In an individual practice:
• Designated person(s) outside clinic (e.g., a network of RNs) who
are covered via Medicare
• Group-setting sessions with a local volunteer HCP to address
general AD questions
• Lunch and learns with willing practitioners to address concerns

• Online assessment tools and questionnaires on major
AD-related websites (e.g., Alzheimer’s Association)
• A checklist of steps or touch points within a patient journey
detailing what is required from the patient at each step to
increase patient confidence
• A forum on national, association-supported portals where
submitted questions are answered by care coordinators
• Name and contact information fields to facilitate follow-up
• Peer-support or mentoring programs for new patients (e.g.,
similar to oncology)

C. Focus area 3: build processes and capacity for integrated care teams
Establish a value case to develop cross-functional teams in
clinic

Educate future dementia-trained HCPs

Key considerations

• A business case to generate senior management support and
buy-in, including the following:
• Direct and indirect costs
• Avoided costs
• Holistic patient cost
• Patient and care partner satisfaction
• Outcomes
• An understanding of different types of patients or cases and
how they might experience the care model
• Decision on inclusion of research component
• Communication of full scope of services for the broader
community
• Clear information flows within the clinic and with external
stakeholders
• IT systems that facilitate cross-team communications
• More efficient intake options, potentially sending patients
packages with tests before their visit so clinic staff can
appropriately identify whom patients should see or if patients
are appropriate for the clinic
• Triaging of patients to the appropriate team resource
• A list of resources and people providing relevant services
• Informational and decisional support

• Curriculum that includes computer-based tools,
neuropsychology tests, and information on conducting LPs
• Interactive video training modules on AD case finding and
diagnosis that NPs/PAs can use
• CME courses for specific diagnosis-related topics
• Annual congresses with dementia-trained HCPs to standardize
and share best practices
• Membership to professional association to share best practices
• Dementia certifications

Potential impact

•
•
•
•

• Larger base of dementia-trained HCPs who can diagnose
dementia

Better outcomes for lower cost
Increased efficiency
Lower total costs when considering patient health in its entirety
Increased readiness for early-stage AD management

AD, Alzheimer’s disease; CME, continuing medical education; HCP, healthcare professional; IT, information technology; LP, lumbar puncture; NP, nurse practitioner; PA, physician
assistant; RN, registered nurse.

accumulating data on normal vs. abnormal cognitive aging that
help to identify risk factors and better characterize the patient
with early-stage AD. Third, non-dementia specialist HCPs should
be trained to take appropriate action early. To create confidence
in available resources and how to deliver care, HCPs will need
additional formal training on the process of AD diagnosis. Clear
guidance should be provided along with practical considerations,
such as tools for conducting cognitive assessments, including the
design of new reimbursement codes focused on early detection
of disease with feasible requirements for primary care providers.
Together, this approach may motivate HCPs to embrace their
role in protecting the cognitive health of their patients by having
discussions about memory and making subsequent referrals to
dementia specialists. Finally, an accessible, step-by-step process
to stratify patient risk and identify patients with early-stage AD
should be adopted to assist HCPs in determining when further
assessment or referral is appropriate.

providers. For non-dementia specialists, a deep understanding
of the potential benefits and barriers to early diagnosis, as well
as the available options for individuals with early-stage AD, is
critical to facilitate early-stage AD detection. We recommend 4
priorities requiring resources and action to improve detection
of early-stage AD (Table 1A). First, awareness of the clinical
value of early detection in the general population must be
accomplished through education about AD and its treatment
options to empower patients to take control of their brain health.
Second, increased education for HCPs on the clinical features of
early-stage disease is imperative. This includes training clinicians
to prompt discussion of cognitive signs and symptoms with their
patients, make use of available dementia screening instruments
that provide a valid and reproducible way to evaluate patients,
recognize the predictive value of subjective concerns, and not
dismiss memory complaints from the patient or family members
who know the patient well. This process will be bolstered by the

Frontiers in Neurology | www.frontiersin.org
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Assess

community resources, and understand other legal and social
support available to the patient.
Disseminating information to increase engagement within the
community is essential to prevent patients from abandoning the
process of early-stage AD diagnosis (Table 1B). The working
group posits that, along with designated care coordinators
within clinics, digital screening approaches may empower
patients for whom seeing a doctor may be uncomfortable or
logistically infeasible. Further community education may help
to destigmatize AD by eliminating the perception that an
individual with AD is elderly or sick. Additionally, the design
of reimbursement codes that expand upon current coverage to
include a diagnostic workup aimed at differentiating AD from
other cognitive disorders may expand the value case for earlystage diagnosis of AD.

Currently, when cognitive impairment is identified at a primary
care appointment, not all patients are referred to a dementia
specialist, in part due to the national shortage of specialists such
as neurologists, geriatricians, and geriatric psychiatrists (4, 22).
To enable HCPs and other specialists to efficiently recognize
potential cognitive impairment and administer screening
assessments (Figure 1B), HCPs should have access to continuing
education and diagnostic tools. To increase capacity, the working
group advocates a new subspecialization of “dementia-trained
HCPs.” Dementia training may be appropriate for a variety of
HCPs, including internists, family medicine physicians, nurse
practitioners, neuropsychologists, and physician assistants, to
work in conjunction with a dementia specialist and alleviate
capacity constraints. Dementia-trained HCPs could assess
cognitive impairment and AD risk by administering a validated
cognitive assessment, possibly accompanied by genetic or
biomarker analysis. In addition to improving capacity,
newly dementia-trained HCPs would be an integral part of
a transdisciplinary care team. Emphasizing the role of wellestablished referral networks and making full use of electronic
health records may reduce communication breakdowns between
providers, which represent a significant barrier to a rapid,
detailed assessment of initial cognitive concerns.

Diagnose
As understanding of AD biomarkers grows, the 2018 update
of the National Institute on Aging and Alzheimer’s Association
research framework for AD diagnosis recommends the
use of biomarkers along with clinical criteria (3) to more
accurately stage AD (Figure 1D). Currently, a positron
emission tomography (PET) scan is the only US Food and Drug
Administration–approved diagnostic biomarker test for AD (14).
Availability and increased use of cerebrospinal fluid biomarkers
of AD may reduce PET imaging facility capacity constraints
(14, 25). Recent granting of US Food and Drug Administration
breakthrough status may increase the use of cerebrospinal fluid
(26) and plasma (27) biomarkers for AD diagnosis. Additionally,
interest in leveraging mobile and wearable digital consumer
technology to facilitate early diagnosis of AD is growing (28).

Differentiate
Diagnoses across the spectrum of AD (e.g., MCI due to AD and
mild dementia due to AD) are based on a comprehensive medical
evaluation that incorporates clinical assessments and considers
alternative causes of disease (1). Initial differential diagnosis
begins with a detailed history and neurologic examination,
followed by cognitive and functional assessments to examine
memory, executive functioning, and behavior (Figure 1C).
Cognitive decline due to AD pathology is often, although not
always, characterized by impaired episodic memory that is not
improved by cueing, which may normalize impaired episodic
memory in other dementia diagnoses (18). Identification of a
cognitive profile suggestive of impairment due to AD is followed
by further assessments to rule out non-AD causes of cognitive
impairment, such as bloodwork analysis for vitamin B12 or
thyroid hormone deficiencies and magnetic resonance imaging
for detection of tumors, stroke, head injury, or pathological
profiles consistent with non-AD dementia (1). During this
process, patients may become overwhelmed. The working group
agreed that it was imperative to develop patient-centered support
within the clinic, outlined in Focus Area 2 (Table 1B).
Establishing designated care partners, or coordinators, within
the care team may ease patient stress associated with the
diagnostic process. Patient-centered collaborative dementia care
has been shown to improve patient stress level and mood
and to reduce depression while improving caregiver confidence
(23, 24). The care coordinator role may be filled by trained
volunteers, social workers, or nurses. Coordinators could help
manage patient expectations by providing support services to
assist with access to care, improve patient education, help
navigate treatment options, connect to support groups and other
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Treat and Monitor
Currently, where a patient with AD enters the healthcare
system greatly influences the care they receive (Figure 1E).
Variation in available management and treatment approaches,
including access to dementia specialists, neuroimaging facilities,
and support groups, is complicated by both geography and
financial resources. In rural and resource-limited areas, added
emphasis on training, both live and virtual, of non-dementia
specialists is vital. The working group recommends building and
strengthening the integrated dementia care team infrastructure
as Focus Area 3 (Table 1C).
The working group acknowledges that for networks and
healthcare systems to be motivated to implement integrated
AD care teams, a strong and clear value case is required
to justify adapting the proposed framework and allocating
additional resources (Table 1C). The large-scale, interventional
Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability (FINGER) trial and post-hoc analyses
of the Multidomain Alzheimer Preventive Trial (MAPT) and
Prevention of Dementia by Intensive Vascular Care (PreDIVA)
trial indicate that multidomain lifestyle interventions for AD
prevention may have a beneficial effect in slowing cognitive
decline in at-risk populations, bolstering the value case for
early intervention even in the absence of a therapy for the
early stages of AD (10, 29–32). In addition to buy-in from
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throughout treatment (35). Adopting this blueprint would also
provide a better framework and increased capacity to apply
the 2015 Gerontological Society of America working group–
recommended Kickstart, Assess, Evaluate, Refer (KAER) model
to increase detection of cognitive impairment and improve
outcomes for Medicare beneficiaries (4).
We recognize the immense challenge of implementing
large-scale, systemic changes, which will require the
cooperation of HCPs, specialists, patients, caregivers, outreach
organizations, and financial stakeholders. Although securing
additional resources to raise awareness of early-stage AD
and developing infrastructure for a patient-centered AD care
team are paramount to supporting patients and their care
partners, many barriers remain. AD must be destigmatized
so patients can seek and understand the benefits of early
detection and intervention while gaining access to early
diagnosis without discrimination. Addressing such barriers
will allow patients to optimally navigate AD diagnosis and
disease management.

key financial stakeholders and the AD healthcare community,
practical infrastructure must be established to create AD care
teams. To address capacity barriers, a program that paired
dementia specialists with dementia-trained HCPs would be the
basis of a broader AD care team (Table 1C) that supports
implementation of strategies to prevent further cognitive decline
and provide immediate access to symptomatic therapies and
future disease-modifying therapies.

LOOKING FORWARD
The numerous unique pathways to AD diagnosis and treatment
motivated the working group’s recommendation for a tailorable,
patient-centered care environment. Indeed, the model presented
here is intended to be optimally efficient but also significantly
flexible to accommodate a real-world setting. We advocate for
HCPs to work as an integrated care team to accommodate
the diverse population of patients with AD, who have varied
entry points to screening and treatment. The successful
implementation of a patient-centered, single-entry-point, nowrong-door model would help identify patients at risk for
cognitive decline and guide patients into care through multiple
initial points of contact (33, 34). A no-wrong-door model would
further streamline AD pathology assessment and differential
diagnosis through the cooperative efforts of public agencies,
outreach organizations, HCPs, payers, and specialists to ensure
that early warning signs of AD are not overlooked. This patientcentric, transdisciplinary care model to diagnose and treat
patients early may also have applicability in other diseases
with large unmet needs, such as cerebrovascular disease and
Parkinson’s disease.
A limitation of the working group recommendations is
the focus on US care models. These recommendations will
need adaptations to fit healthcare systems of other countries.
However, the proposed AD care team aligns with multiple
action areas of the World Health Organization’s 2017 Global
Action Plan on the Public Health Response to Dementia, which
emphasizes the need for dementia awareness, risk reduction,
and support for those with dementia and their caregivers
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